During the last three months, 11 analysts shared their evaluations of Keros Therapeutics KROS, revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 6 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 1 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 2 | 3 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $54.91, a high estimate of $111.00, and a low estimate of $15.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 29.52%.
Investigating Analyst Ratings: An Elaborate Study
The standing of Keros Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Catanzaro | Piper Sandler | Lowers | Overweight | $15.00 | $40.00 |
| Andreas Argyrides | Wedbush | Lowers | Neutral | $15.00 | $47.00 |
| Greg Harrison | Scotiabank | Lowers | Sector Outperform | $41.00 | $44.00 |
| Andreas Argyrides | Oppenheimer | Lowers | Outperform | $23.00 | $63.00 |
| Srikripa Devarakonda | Truist Securities | Lowers | Buy | $43.00 | $100.00 |
| Andreas Argyrides | Oppenheimer | Lowers | Outperform | $63.00 | $102.00 |
| Greg Harrison | Scotiabank | Lowers | Sector Outperform | $44.00 | $77.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $47.00 | $100.00 |
| Tiago Fauth | Wells Fargo | Raises | Overweight | $111.00 | $88.00 |
| Vamil Divan | Guggenheim | Raises | Buy | $102.00 | $96.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $100.00 | $100.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Keros Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Keros Therapeutics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Keros Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Keros Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Keros Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Keros Therapeutics
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Keros Therapeutics's Economic Impact: An Analysis
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Keros Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4750.0%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Keros Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -13648.45%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Keros Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -11.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Keros Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.24%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.04, Keros Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst Ratings: What Every Investor Should Know
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
